XML 24 R16.htm IDEA: XBRL DOCUMENT v3.26.3
Segment Reporting
9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Segment Reporting

6. Segment Reporting

The Company operates as a single operating segment, which is the business of developing and commercializing therapeutics. The Company’s chief operating decision maker ("CODM"), its chief executive officer, reviews financial information on an aggregate basis for the purpose of allocating resources and assessing performance. When deciding how to allocate resources, the CODM reviews the financial results of the Company's drug candidate programs. The measure of segment assets is reported on the consolidated balance sheet as total assets.

The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Research and development expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Lasofoxifene

 

$

10,536

 

 

$

—

 

 

$

28,274

 

 

$

—

 

Fosgonimeton (ATH-1017)

 

 

20

 

 

 

317

 

 

 

209

 

 

 

2,180

 

Brelgometon (ATH-1105)

 

 

280

 

 

 

673

 

 

 

817

 

 

 

2,834

 

ATH-1020

 

 

—

 

 

 

—

 

 

 

—

 

 

 

5

 

Preclinical programs and other costs

 

 

734

 

 

 

268

 

 

 

1,553

 

 

 

928

 

Milestone liability change in fair value

 

 

(411

)

 

 

—

 

 

 

(1,165

)

 

 

—

 

Personnel-related costs, excluding stock-
   based compensation

 

 

2,346

 

 

 

895

 

 

 

5,701

 

 

 

2,811

 

Total research and development expenses

 

 

13,505

 

 

 

2,153

 

 

 

35,389

 

 

 

8,758

 

General and administrative expenses

 

 

4,153

 

 

 

3,067

 

 

 

14,635

 

 

 

9,569

 

Other segment expenses(a)

 

 

3,809

 

 

 

1,654

 

 

 

8,110

 

 

 

5,374

 

Total operating expenses

 

 

21,467

 

 

 

6,874

 

 

 

58,134

 

 

 

23,701

 

Loss from operations

 

 

(21,467

)

 

 

(6,874

)

 

 

(58,134

)

 

 

(23,701

)

Other income, net

 

 

303

 

 

 

263

 

 

 

1,335

 

 

981

 

Sermonix pre-funded warrant change in
   fair value

 

 

—

 

 

 

—

 

 

 

(16,320

)

 

 

—

 

Net loss

 

$

(21,164

)

 

$

(6,611

)

 

$

(73,119

)

 

$

(22,720

)

 

(a) Other segment expenses includes stock-based compensation and depreciation expenses.